BIOSIM
Selective Biochip with portable analyzer for assessment of insulin resistance and the metabolic syndrome (BIOSIM).
Programme PN III: Programme 2- Increasing the Romanian Economy Competitiveness by Research, Development and Innovation.
Project Type: Transfer from economic operator.
Project financed by the state budged and co-financed by DDS Diagnostic.
Contract No. 50PTE/2016
Period: 2016-2018
Coordinator: S.C. DDS DIAGNOSTIC S.R.L Bucharest.
Project Director: Phd. Dana Stan
Main Purpose of the Project
The main purpose of this project is to develop and certify a new technology for the manufacturing of portable selective biochips and of the portable tester, for the assessment of the insulin resistance and a metabolic syndrome, up to TRL5.
Main Targets of the Project:
1. Development of a prototype based on new technologies for the manufacturing of integrated biochips, starting from the outcomes of the scientific research carried out by DDS Diagnostic and IMT.
2. Development of a partnership between the coordinating institution (IMM) and the research institutions for the creation of state of the art technology, for the quick transfer thereof to the industrial partner to be traded on the internal and external market.
3. Development of a new, accessible, easy to use technology with quick responses, low costs and immediate application in the early assessment and diagnosis of the insulin resistance and metabolic syndrome.
4. Testing and classification of the new technology for the detection of insulin resistance and metabolic syndrome assessment biomarkers.
5. Interpretation, validation of outcomes and correlation thereof with current clinical analysis; Transfer of technology.
6. Outcome Dissemination.
2. Development of a partnership between the coordinating institution (IMM) and the research institutions for the creation of state of the art technology, for the quick transfer thereof to the industrial partner to be traded on the internal and external market.
3. Development of a new, accessible, easy to use technology with quick responses, low costs and immediate application in the early assessment and diagnosis of the insulin resistance and metabolic syndrome.
4. Testing and classification of the new technology for the detection of insulin resistance and metabolic syndrome assessment biomarkers.
5. Interpretation, validation of outcomes and correlation thereof with current clinical analysis; Transfer of technology.
6. Outcome Dissemination.